US Stem Cell Inc (USRM)

[InvestorStemCell]

Investing in Bioheart, Inc. $$$$$MUSTREAD$$$$
RegMed companies are in fact the paradigm shift in healthcare and will literally reshape mankind as we know it by extending lives beyond 140 years of age. The Stem Cell investment sector is still under the radar as the digital age was in 1993. Before the World Wide Web saturated our world, YHOO traded at $0.43 a share in 1996 and three years later it traded at $105.00 a share. Ask yourself how much a company is worth that can heal a broken heart? $90 Billion? $500 Billion? A Trillion Dollars or more?

How much would you pay for a treatment that will regenerate your damaged heart and allow you to breath air for another 30 years of life? Stem Cell science is the medical technology that is here today and not just in a Star Trek movie that takes place in 2456. Tens of thousands travel off-shore from the USA every year to secure these stem cell treatments due to the FDA being hooked on a platform of synthetic drugs and protocols established in the 1950’s. In the next 24 months this will all change forever as Bioheart and other RegMed companies break through and achieve FDA validation of cellular treatments using our own cells to treat disease. Big Pharma will be turned upside on their cumulative heads and will be forced to pay hundreds of billions of dollars for this technology.

Like the DotCom boom, NEXT BIG THING is Regenerative Medicine, are you ready?

Putting it all together – Bioheart, Inc. (OTCMKTS:BHRT) Is now the time for investment? Lets discuss the reasoning why your receiving this email. On October 24, 2014 16:00 ET, after market close, a promising but financially restricted microcap announced that it had closed on a $3,000.000.00 financing commitment from Magna LLC. ( www.magnallc.com ) That Company is Bioheart, Inc. (OTCMKTS:BHRT) Please review the SEC filing and take note that Magna is not receiving an extraordinary discount, only 7%! For those that follow stocks this discount means Magna feels strongly about the upside of Bioheart share appreciation.

http://www.sec.gov/Archives/edgar/data/1388319/000114544314001254/e61149_8k.htm

Picking the right time to invest is predicated upon spotting milestones that have surfaced in the past with other companies and being able to match those events with other public companies before the market puts 2 + 2 = INVESTMENT. Buying stock in break-out companies is similar to musical chairs we played as children, the less chairs available the more demand and furry to secure chairs/stock. This is why when thinly traded companies achieve awareness the share price explodes.

HISTORY DOES REPEAT ITSELF! Nuvilex, Inc.(OTCMKTS:NVLX) was Bioheart Inc so to speak in every way except in name in 12/2012 until it closed and received its first installment of a $3,500.000.00 share purchase agreement. Nuvilex was trading around $0.02 a share, it had an outstanding share balance of 552,000,000 shares and two months after the late December-2012 8K filing NVLX would go from $0.02 to a high of $0.59 a share 60 days after 1st receiving the initial installment! So why does this happen? Why do microcaps explode in value? Here is some insight…. Right now BHRT is trading at a valuation of $9,000,000.00, yet Bioheart’s sector rivals with similar clinical research and assets trade upwards of $80,000,000.00 on the low end in valuation. Please note that NVLX is trading over $179.64M valuation. Bioheart does not have free cash flow as these other companies do which would allow Bioheart to engage with investor relations companies. These I/R companies promote company stocks non-stop on social media as well as email campaigns, paid article submissions and numerous other channels of awareness. These I/R-services cost $40,000.00 per month on the low side and upwards of $100,000.00 or more! Based upon the financials

Bioheart has been dependent upon Broker-Dealers often referred to as “hard-money” to fulfill its monthly cash-burn requirements for several years also personal investment of its Insider-Mgt. which we will discuss further below. These brokers receive conversion discounts of 40-60% off the share price and as such have little or no reason to “Promote” the company so as to ensure the BD’s are spending the least to garner the highest returns. If you have read Magnum’s share purchase agreement you will notice that Bioheart is only giving Magnum a 7% discount when it buys BHRT-common stock of which Magnum will take and sell into the open market. Why does this matter to you? Think about it, Magnum could never stay in business on a 7% margin of return in the micro-cap world.

To that end, Magnum will undoubtedly either hire its own Investor Services to promote Bioheart or Bioheart will do so internally? Either way this is a HUGE win for investors that buy in early before the inevitable upcoming spike valuation! More than Just the $$$’s –

Investing in the People- If you viewed only the Executive Management – Board of Directors at Bioheart you could easily assume you were reviewing the credentials of a Fortune 500 Company and not a microcap stock. You can review the Insiders here- http://www.bioheartinc.com/ please contemplate the questions I have asked below. How does a microcap such as Bioheart attract a Chairman of the Board of Dr. William P. Murphy Jr. caliber? http://en.wikipedia.org/wiki/William_P._Murphy_Jr. Dr. Murphy is responsible for inventions that are common place now in life sciences. His work has reshaped health care time and again over the past 7 decades. He is responsible for saving the lives of millions through creation of standard of care devices, including the first physiologic cardiac pacemaker – the widely used hollow fiber artificial kidney, the first disposable medical procedural trays, the first motor-driven angiographic injectors, first disposable catheters, and the modern blood transfusion bags to name just a few of his inventions and developments over the past 70 years.

So again, ask yourself, why has Dr. Murphy at the twilight of his life placed his exceptional good-name on a microcap biotech and invested several million dollars of his own personal fortune?

Why does Mike Tomas the CEO take all compensation in BHRT common stock? Does he see a future with a world where Bioheart’s cellular delivery products are 1st in class? http://www.bioheartinc.com/AboutUs/Management/MikeTom%c3%a1s


How does Bioheart retain a renowned Chief Science Officer like Kristin Comella? http://www.bioheartinc.com/AboutUs/Management/KristinComella

I am of the opinion that these incredible individuals have spied the future, a world where healthcare no longer comes from synthetic drugs. The personal and financial commitment by the insiders is a clear indication they feel strongly that Bioheart, Inc. (OTC-BHRT) stands poised to fundamentally transform treatment to those battling acute heart failure. I see the potential based upon previous instances of other companies in the RegMed sector for a possible drastic market cap valuation increase in value in BHRT in the coming months. As always these are my opinions. Before investing please consult a licensed investment professional and consider all risks before investing.

Bioheart’s Corporate Health > Ticker Symbol of Bioheart, Inc. is BHRT Last trade $0.016 > Current liabilities down $3.6 million (27%) from beginning of year. Down 49% in 24 months from high of $13.6m > Working capital deficit improved by 28% from beginning of year > Revenue up by 2,369% comparing 2nd quarter 2014 to 2nd quarter 2013 > Revenue up by 3,670% comparing YTD 2014 to YTD 2013 > Net loss down 39.8% comparing 2nd quarter 2014 to 2nd quarter 2013 > Generated over $1m in revenues so far this year-from $0 last year as compared to net loss of $1,269,231 YTD 2013 > Cash used in operating activities of $507K in YTD 2014 as compared to $1,095K in YTD 2013; down by 54% > Eliminated development stage reporting, no longer inception to date statements of operations or cash flows > At the next 10K the removal of “Going Concern Classification” will be removed > Revenue creation; Just this year, opened clinics or signed partnerships with healthcare organizations in Australia, Honduras, South Africa, Colombia, Turkey, Azerbaijan and 2 new cities in Mexico > Initiated trials in several new indications including dry macular degeneration and erectile dysfunction > Completed ANGEL trial and 3, 6 and 12 month results overwhelmingly positive